(2011) in a cohort study with 138 patients found significant improvements in treatment satisfaction (p < 0.05) and well‐being (p < 0.05) after 6 months of exenatide treatment compared to insulin, with Hospital Anxiety and Depression Scale (HADS) scores that were also significantly reduced in the exenatide group (p < 0.05). This evidence concerns the gene INS and major depressive disorder.